Long-term effects of irbesartan on plasma aldosterone concentration and left atrial volume in hypertensive patients

Journal of Cardiology

Volumn 63, Issue 3, 2014, Pages 205-210

  Masaki, Mitsuru ^a   Komamura, Kazuo ^a,b   Goda, Akiko ^a   Hirotani, Shinichi ^a   Otsuka, Misato ^a   Nakabo, Ayumi ^a   Fukui, Miho ^a   Fujiwara, Shohei ^a   Sugahara, Masataka ^a   Lee Kawabata, Masaaki ^a   Tsujino, Takeshi ^a   Koshiba, Masahiro ^a   Masuyama, Tohru ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Aldosterone; Angiotensin type II receptor blocking drugs; Calcium channel blocking drugs; Hypertension; Left atrial volume

Indexed keywords

ALDOSTERONE; AMLODIPINE; BRAIN NATRIURETIC PEPTIDE; IRBESARTAN;

ADULT; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; HEART ATRIUM REMODELING; HEART LEFT ATRIUM VOLUME INDEX; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; LONG TERM CARE; MALE; MONOTHERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION;

ALDOSTERONE; ANGIOTENSIN TYPE II RECEPTOR BLOCKING DRUGS; CALCIUM CHANNEL BLOCKING DRUGS; HYPERTENSION; LEFT ATRIAL VOLUME;

AGED; ALDOSTERONE; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ATRIAL REMODELING; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; FEMALE; HEART ATRIA; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; TETRAZOLES; TIME FACTORS;

EID: 84896696309     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2013.08.004     Document Type: Article

References (41)

1. Kenchaiah S., Pfeffer M.A. Cardiac remodeling in systemic hypertension. Med Clin North Am 2004, 88:115-130.
2. Cetin M., Kocaman S.A., Durakoglugil M.E., Erdogan T., Ergul E., Dogan S., Canga A. Effect of epicardial adipose tissue on diastolic functions and left atrial dimension in untreated hypertensive patients with normal systolic function. J Cardiol 2013, 61:359-364.
3. Cohn J.N., Ferrari R., Sharpe N. Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000, 35:569-582.
4. Matsuzaki M., Yamamoto K., Yano M., Nakamura K., Miyata Y., Sugiura K., Nakata E., Tsutsui H. Efficacy and safety of a 60-week treatment with candesartan in Japanese patients with mild to moderate chronic heart failure. J Cardiol 2013, 61:267-274.
5. Gerdts E., Wachtell K., Omvik P., Otterstad J.E., Oikarinen L., Boman K., Dahlof B., Devereux R.B. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial. Hypertension 2007, 49:311-316.
6. Tsang T.S., Barnes M.E., Abhayaratna W.P., Cha S.S., Gersh B.J., Langins A.P., Green T.D., Bailey K.R., Miyasaka Y., Seward J.B. Effects of quinapril on left atrial structural remodeling and arterial stiffness. Am J Cardiol 2006, 97:916-920.
7. Delcayre C., Silvestre J.S., Garnier A., Oubenaissa A., Cailmail S., Tatara E., Swynghedauw B., Robert V. Cardiac aldosterone production and ventricular remodeling. Kidney Int 2000, 57:1346-1351.
8. Yoshida C., Goda A., Naito Y., Nakaboh A., Matsumoto M., Otsuka M., Ohyanagi M., Hirotani S., Lee-Kawabata M., Tsujino T., Masuyama T. Role of plasma aldosterone concentration in regression of left-ventricular mass following antihypertensive medication. J Hypertens 2011, 29:357-363.
9. Benjamin E.J., D'Agostino R.B., Belanger A.J., Wolf P.A., Levy D. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation 1995, 92:835-841.
10. Tsang T.S., Barnes M.E., Bailey K.R., Leibson C.L., Montgomery S.C., Takemoto Y., Diamond P.M., Marra M.A., Gersh B.J., Wiebers D.O., Petty G.W., Seward J.B. Left atrial volume: important risk marker of incident atrial fibrillation in 1655 older men and women. Mayo Clin Proc 2001, 76:467-475.
11. Verdecchia P., Reboldi G., Gattobigio R., Bentivoglio M., Borgioni C., Angeli F., Carluccio E., Sardone M.G., Porcellati C. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003, 41:218-223.
12. Laukkanen J.A., Kurl S., Eranen J., Huttunen M., Salonen J.T. Left atrium size and the risk of cardiovascular death in middle-aged men. Arch Intern Med 2005, 165:1788-1793.
13. Nishino M., Mori N., Nakamura D., Lee Y., Yoshimura T., Taniike M., Makino N., Kato H., Egami Y., Shutta R., Tanouchi J., Yamada Y. Correlation between inflammation state and successful medical cardioversion using bepridil for refractory atrial fibrillation. J Cardiol 2013, 62:117-120.
14. Schiller N.B., Shah P.M., Crawford M., DeMaria A., Devereux R., Feigenbaum H., Gutgesell H., Reichek N., Sahn D., Schnittger I., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-dimensional Echocardiograms. J Am Soc Echocardiogr 1989, 2:358-367.
15. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., Picard M.H., Roman M.J., Seward J., Shanewise J.S., Solomon S.D., Spencer K.T., Sutton M.S., Stewart W.J. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18:1440-1463.
16. Takemoto Y., Barnes M.E., Seward J.B., Lester S.J., Appleton C.A., Gersh B.J., Bailey K.R., Tsang T.S. Usefulness of left atrial volume in predicting first congestive heart failure in patients > or =65 years of age with well-preserved left ventricular systolic function. Am J Cardiol 2005, 96:832-836.
17. Gottdiener J.S., Kitzman D.W., Aurigemma G.P., Arnold A.M., Manolio T.A. Left atrial volume, geometry, and function in systolic and diastolic heart failure of persons > or =65 years of age (the cardiovascular health study). Am J Cardiol 2006, 97:83-89.
18. Zile M.R., Gottdiener J.S., Hetzel S.J., McMurray J.J., Komajda M., McKelvie R., Baicu C.F., Massie B.M., Carson P.E. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 2011, 124:2491-2501.
19. Vaziri S.M., Larson M.G., Benjamin E.J., Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation 1994, 89:724-730.
20. Pritchett A.M., Mahoney D.W., Jacobsen S.J., Rodeheffer R.J., Karon B.L., Redfield M.M. Diastolic dysfunction and left atrial volume: a population-based study. J Am Coll Cardiol 2005, 45:87-92.
21. Tsang T.S., Barnes M.E., Gersh B.J., Bailey K.R., Seward J.B. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol 2002, 90:1284-1289.
22. Tsang M.Y., Barnes M.E., Tsang T.S. Left atrial volume: clinical value revisited. Curr Cardiol Rep 2012, 14:374-380.
23. Douglas P.S. The left atrium: a biomarker of chronic diastolic dysfunction and cardiovascular disease risk. J Am Coll Cardiol 2003, 42:1206-1207.
24. Raman S.V. The hypertensive heart. An integrated understanding informed by imaging. J Am Coll Cardiol 2010, 55:91-96.
25. Dluhy R.G., Williams G.H. Aldosterone-villain or bystander?. N Engl J Med 2004, 351:8-10.
26. Malmqvist K., Kahan T., Edner M., Held C., Hagg A., Lind L., Muller-Brunotte R., Nystrom F., Ohman K.P., Osbakken M.D., Ostergern J. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001, 19:1167-1176.
27. Muller-Brunotte R., Kahan T., Lopez B., Edner M., Gonzalez A., Diez J., Malmqvist K. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J Hypertens 2007, 25:1958-1966.
28. Westermann D., Rutschow S., Jager S., Linderer A., Anker S., Riad A., Unger T., Schultheiss H.P., Pauschinger M., Tschope C. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 2007, 56:641-646.
29. Clasen R., Schupp M., Foryst-Ludwig A., Sprang C., Clemenz M., Krikov M., Thone-Reineke C., Unger T., Kintscher U. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005, 46:137-143.
30. Oudit G.Y., Kassiri Z., Patel M.P., Chappell M., Butany J., Backx P.H., Tsushima R.G., Scholey J.W., Khokha R., Penninger J.M. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res 2007, 75:29-39.
31. Kumagai K., Nakashima H., Urata H., Gondo N., Arakawa K., Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003, 41:2197-2204.
32. Kato T., Yamashita T., Sekiguchi A., Tsuneda T., Sagara K., Takamura M., Kaneko S., Aizawa T., Fu L.T. Angiotensin II type 1 receptor blocker attenuates diabetes-induced atrial structural remodeling. J Cardiol 2011, 58:131-136.
33. Lefrandt J.D., Heitmann J., Sevre K., Castellano M., Hausberg M., Fallon M., Fluckiger L., Urbigkeit A., Rostrup M., Agabiti-Rosei E., Rahn K.H., Murphy M., Zannad F., de Kam P.J., van Roon A.M., Smit A.J. The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study. Am J Hypertens 2001, 14:1083-1089.
34. Struck J., Muck P., Trubger D., Handrock R., Weidinger G., Dendorfer A., Dodt C. Effects of selective angiotensin II receptor blockade on sympathetic nerve activity in primary hypertensive subjects. J Hypertens 2002, 20:1143-1149.
35. Takahara A., Nakamura Y., Wagatsuma H., Aritomi S., Nakayama A., Satoh Y., Akie Y., Sugiyama A. Long-term blockade of L/N-type Ca(2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart. Br J Pharmacol 2009, 158:1366-1374.
36. Nishimura R.A., Schwartz R.S., Holmes D.R., Tajik A.J. Failure of calcium channel blockers to improve ventricular relaxation in humans. J Am Coll Cardiol 1993, 21:182-188.
37. Chen Y., Sato H., Watanabe N., Adachi T., Kodani N., Sato M., Takahashi N., Kitamura J., Yamaguchi K., Yoshitomi H., Tanabe K. Factors influencing left atrial volume in treated hypertension. J Cardiol 2012, 60:133-138.
38. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., Ritz E., Atkins R.C., Rohde R., Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
39. Wachtell K., Lehto M., Gerdts E., Olsen M.H., Hornestam B., Dahlof B., Ibsen H., Julius S., Kjeldsen S.E., Lindholm L.H., Nieminen M.S., Devereux R.B. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005, 45:712-719.
40. Schmieder R.E., Kjeldsen S.E., Julius S., McInnes G.T., Zanchetti A., Hua T.A. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 2008, 26:403-411.
41. Schneider M.P., Hua T.A., Bohm M., Wachtell K., Kjeldsen S.E., Schmieder R.E. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010, 55:2299-2307.